Match!
José Ramón Arribas
Hospital Universitario La Paz
259Publications
40H-index
6,509Citations
Publications 259
Newest
#1Joseph J. Eron (UNC: University of North Carolina at Chapel Hill)H-Index: 82
#2Chloe Orkin (QMUL: Queen Mary University of London)H-Index: 31
Last.Romana Petrovic (Janssen Pharmaceutica)H-Index: 3
view all 10 authors...
Abstract Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants in the boosted PI arm were offered switch to D/C/F/T...
#1Richard T. DaveyH-Index: 58
#2Eduardo Fernández-Cruz (Hospital General Universitario Gregorio Marañón)
Last.Mamta K. Jain (UTSW: University of Texas Southwestern Medical Center)H-Index: 19
view all 10 authors...
Summary Background Since the 1918 influenza pandemic, non-randomised studies and small clinical trials have suggested that convalescent plasma or anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) might have clinical benefit for patients with influenza infection, but definitive data do not exist. We aimed to evaluate the safety and efficacy of hIVIG in a randomised controlled trial. Methods This randomised, double-blind, placebo-controlled trial was planned for 45 hospitals in Argenti...
#1Jens H. Kuhn (NIH: National Institutes of Health)H-Index: 41
#2Takuya AdachiH-Index: 4
Last.Nahid Bhadelia (BU: Boston University)H-Index: 7
view all 10 authors...
The recent large outbreak of Ebola virus disease (EVD) in Western Africa resulted in greatly increased accumulation of human genotypic, phenotypic and clinical data, and improved our understanding of the spectrum of clinical manifestations. As a result, the WHO disease classification of EVD underwent major revision.
#1Jennifer Thompson (UCL: University College London)H-Index: 9
#2Cissy KityoH-Index: 30
Last.José Ramón ArribasH-Index: 40
view all 10 authors...
BACKGROUND: Limited viral load (VL) testing in HIV-infected individuals on treatment in low-income countries often results in late detection of treatment failure. The impact of remaining on failing second-line, protease inhibitor (PI) containing regimens is unclear. METHODS: We retrospectively tested VL from 2,164 stored plasma samples from 386 patients randomised to receive PI-monotherapy (ritonavir-boosted lopinavir, after initial PI+raltegravir induction) in the EARNEST trial. Protease genoty...
#2Esteban Martínez (University of Barcelona)H-Index: 46
Last.Fernando LozanoH-Index: 21
view all 10 authors...
Abstract Background The GESIDA/National AIDS Plan expert panel recommended preferred regimens (PR), alternative regimens (AR) and other regimens (OR) for antiretroviral treatment (ART) as initial therapy in HIV-infected patients for 2018. The objective of this study was to evaluate the costs and the efficiency of initiating treatment with PR and AR. Methods Economic assessment of costs and efficiency (cost-effectiveness) based on decision tree analyses. Effectiveness was defined as the probabili...
Abstract This update to the document on antiretroviral therapy (ART) in adults, which has been prepared jointly by GeSIDA and the Spanish National AIDS Plan for the last two decades, supersedes the document published in 2017. 1 The update provides physicians treating HIV-1-infected adults with evidence-based recommendations to guide their therapeutic decisions. The main difference with respect to the previous document concerns recommended initial ART regimens, only three of which are maintained ...
#1Fernando Lázaro-Perona (Hospital Universitario La Paz)H-Index: 3
#2Juan Carlos Ramos Ramos (Hospital Universitario La Paz)H-Index: 2
Last.Arnalich F (Hospital Universitario La Paz)H-Index: 27
view all 10 authors...
Summary To study intestinal colonization by OXA-48-producing Klebsiella pneumoniae (KpO48) after hospital discharge, stool samples from 22 previously colonized subjects were collected. Time from discharge was 33–611 days, without readmissions. Eight subjects (36%) were identified as bla OXA-48 gene carriers. In all of them the hospital-acquired strain of KpO48 had been lost, and the gene was harboured by other strains of K. pneumoniae , Klebsiella oxytoca and/or Escherichia coli . Our findings s...
12345678910